Unruptured Intracranial Aneurysm Treatment Market

The global unruptured intracranial aneurysm treatment market in 2020 is estimated for more than US$ 1,027.1 Mn and expected to reach a value of US$ 1,937.4 Mn by 2028 with a significant CAGR of 8.3%


Reports and Insights (R&I) has published a new report titled, Unruptured Intracranial Aneurysm Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028

Global Unruptured Intracranial Aneurysm Treatment Market, by Treatment Type (Endovascular Therapy, Surgical Clipping, Flow Diversion Stents, Medicines), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

As per the report, hypertension is identified as the major risk factor for intracranial aneurysm, and mounting prevalence of hypertension is in part attributed to growth of unruptured intracranial aneurysm treatment market. Some other risk factors for intracranial aneurysm are cigarette smoking, genetic predisposition, trauma/injury to cranial blood vessels, blood infection etc. Intracranial aneurysm is a cerebrovascular disorders characterized by bulging or localized dilation of cerebral artery due to weakness in wall of the artery.

Unruptured intracranial aneurysms (UIA) are a common finding and occur in about 2% of the population. The estimated prevalence of unruptured intracranial aneurysms is approximately 3.2% in the general population, but may be higher in older patients, females, and patients with family history or certain genetic conditions. If less than 10 mm, unruptured aneurysms often remain asymptomatic. Large aneurysm can present with symptoms including headache, seizure, cranial nerve palsies, cerebral ischemic events etc. Aneurysm rupture resulting in subarachnoid hemorrhage (SAH) is the most serious consequence of unruptured intracranial aneurysm. Subarachnoid hemorrhage occurs at a rate of approximately 6–10/100,000 person-years. The fatality rate for subarachnoid hemorrhage is around 30% to 40%.

Furthermore, Reports and Insights (R&I) Study identifies that, surgical clipping of the aneurysm is the most common treatment type for unruptured intracranial aneurysm. Until 1995, surgical clipping was the only method available for treatment of unruptured intracranial aneurysm. However, recent technological advances such as introduction of less invasive endovascular therapy and flow diversion stents would push the market for unruptured intracranial aneurysm treatment. Endovascular therapy involves coiling of aneurysm. These coils are deployed into an aneurysm via a microcatheter that is inserted through the femoral artery of the leg and gradually advanced into the brain. Endovascular therapy/coiling is expected to be the choice of treatment for unruptured intracranial aneurysm because it does not require opening of the skull and require less time.

However, it renders the chances of recanalization. Hence, surgical clipping is still preferred over endovascular therapy. Flow diversion stents were introduced in 2000s. Antihypertensive medicines are recommended in patients with hypertension and unruptured intracranial aneurysm, along with diet and exercise program.

R&I Study identifies some of the key participating players in unruptured intracranial aneurysm treatment market globally are ev3 Inc., Balt USA LLC., Stryker Corporation, MicroVention, Inc., Aesculap, Inc. (B. Braun), adeor medical AG, C R Bard, Penumbra, Inc., DePuy Synthes etc,

About Reports and Insights (R&I):

Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Reports and Insights (R&I)

Tel: +1-(281)-619-8646

For Sales Queries: [email protected]

For New Topics and Other Info: [email protected]

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy